The Impact of Homologous Recombination Deficiency on First-line Adjuvant Chemotherapy and First-line PARPi Maintenance Therapy in Chinese Patients with Epithelial Ovarian Cancer
Li, L.; Gu, Y.; Zhang, M.; Shi, X.; Li, Z.; Xu, X.; Sun, T.; Dong, Y.; Xue, C.; Zhu, X.; Lv, R.; Jiao, K.; Ji, X.; Liang, Z.; Jin, Y.; Yin, R.; Wu, M.; Liang, H.
Show abstract
Homologous recombination deficiency (HRD) testing has been approved by FDA for selecting epithelial ovarian cancer (EOC) patients who may benefit from the first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. However, the effects of HRD on the clinical outcomes of first-line chemotherapy and first-line PARPi maintenance therapy have not been rigorously evaluated in Chinese EOC patients. Here, we developed an HRD assay and applied it to two large Chinese EOC patient cohorts. In the first-line adjuvant chemotherapy cohort (FACT, N = 380), HRD status significantly improved PFS (median, 15.6 months vs. 9.4 months; HR, 0.688; 95% CI, 0.526 to 0.899; P = 0.003) and OS (median, 89.5 months vs. 60.9 months; HR, 0.636; 95% CI, 0.423 to 0.955; P = 0.008). In the first-line PARPi maintenance therapy cohort (FPMT, N = 83), HRD status significantly improved PFS (median, NA vs 12 months; HR, 0.438; 95% CI, 0.201 to 0.957; P = 0.033) and OS (median, NA vs NA months; HR, 0.12; 95% CI, 0.029 to 0.505; P = 0.001). Our results demonstrate that HRD status is a significant predictor for PFS and OS in both first-line chemotherapy and first-line PARPi maintenance therapy, providing strong real-world evidence for conducting genetic testing and improving clinical recommendations for Chinese EOC patients.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 93%
- Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations 93%
- Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer 92%
Similar papers in this journal
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 94%
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 94%
- Self-Supervised Learning Reveals Clinically Relevant Histomorphological Patterns for Therapeutic Strategies in Colon Cancer 94%
Similar papers in this journal
- Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences 94%
- Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma 93%
- Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer 92%
Similar papers in this journal
- "3G" Trial: An RNA Editing Signature for Guiding Gastric Cancer Chemotherapy 94%
- Spatiotemporal Response Heterogeneity Across Metastatic Lesions Informs Drug Efficacy and Patient Survival in Colorectal Cancer 94%
- Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma 94%
Similar papers in this journal
- A three gene signature predicts response to selinexor in multiple myeloma 92%
- 5-hydroxymethylcytosine profiling of cell-free DNA identifies bivalent genes that are prognostic of survival in high-risk neuroblastoma. 92%
- Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.